The humoral antibody response of feline leukemia virus (FeLV)exposed cats to the feline oncornavirusassociated tumor cell-membrane antigen (FOCMA) is directly correlated with immunosurveillance against tumor development under natural conditions. By means of membrane immunofluorescence and radioimmunoprecipitation, the antibody response to FOCMA was found to be independent of the antibody response to the major envelope and core proteins of FeLV, gp70 and p3. This was especially true for healthy viremic cats, wbere antigenemia with circulating FeLV gp7O and p30 apparently binds any free antibody to these proteins, but high levels of FOCMA antibody are often concurrently present. Exhaustive in vitro absorption of highly immune nonviremic serum with gp70 and p30 also failed to remove FOCMA antibody activity. These results indicate that FOCMA is not one of these major FeLV structural proteins.
Exposure of cats to the feline leukemia (FeLV) and sarcoma (FeSV) viruses usually results in expression of the feline oncornavirus-associated cell-membrane antigen (FOCMA) (1) (2) (3) (4) (5) . This occurs both following laboratory inoculation with concentrated live virus preparations (6-10) and after horizontal contact exposure to virus under laboratory (6, 9, 11, 12) and field conditions (13) (14) (15) . The levels of FOCMA antibody detected in sera of virus-exposed cats have been shown to be predictive of tumor occurrence and growth. High FOCMA antibody titers appear to be protective against tumor development. Thus, the immune response to FOCMA appears to function as an immunosurveillance mechanism under natural conditions to prevent leukemia development following exposure to FeLV (3, 15) .
The nature of FOCMA is as yet unknown. This antigen is found in fresh biopsies of tumors etiologically associated with FeLV and/or FeSV and on FeLV-producing feline lymphoblastoid tumor cells in culture (1, 16) . Since sera containing FOCMA antibody have generally been obtained from animals exposed to FeLV, the possibility that FOCMA represents a FeLV-structural protein(s) has been difficult to exclude. The envelope glycoprotein of type C viruses, designated gp7O, is expressed on the surface of type-C-virus-producing cells, and antisera to gp7O have been shown to be cytotoxic under appropriate conditions to type-C-virus-releasing cells (17, 18) . Moreover, there has been a recent report implicating FeLV gp7O as FOCMA (19) .
The development of radioimmunoassays utilizing specific type C viral structural proteins has made it possible to quantitatively measure antibodies to different viral proteins. Moreover, in Sera. Sera from FeLV-exposed cats were obtained from several sources, including two leukemia cluster households (14) and the Angell Memorial Animal Hospital, Boston, Mass. (21) . The sera were classified as viremic or nonviremic on the basis of a fixed cell fluorescence antibody test for FeLV proteins associated with blood leukocytes and platelets (22, 23) . Serial serum samples were obtained from a healthy 4-month-old cat obtained from a "FeLV-free" commercial colony (24) following its introduction to a "leukemia cluster" household. All serum samples were coded and assayed for antibody and antigen activity in a double-blind fashion. Goat antiserum against Tween-80-disrupted Theilen strain of FeSV (FeLV), pig antigoat IgG, and goat anti-cat IgG were provided by R. Wilsnack, Huntington Laboratories, through the courtesy of J. Gruber, Office of Resources and Logistics, National Cancer Institute.
Purification of FeLV gp7O and p30. Approximately 5 mg of purified FeSV(FeLV) was disrupted by incubation at 370 for 30 min with buffer containing 0.05 M Tris-HCI, pH 8.9, 0.01 M EDTA, 1.0 M NaCI, and 0.5% Triton X-100, and then centrifuged at 30,000 rpm for 30 min in a Beckman T40 rotor. The supernatant was dialyzed against 0.01 M N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid-NaOH at pH 6.5, 0.001 M EDTA, and 0.1% Triton X-100 (BET buffer) at 40 for 18 hr, and loaded on a 1.0 X 5.0 cm phosphocellulose column (Whatman, P11) equilibrated with BET buffer. After washing with 50 ml of the same buffer, proteins were eluted with a 0.0-1.0 M linear KCI gradient in BET buffer (100 ml) at a flow rate of 10 ml/hr. The elution patterns of gp7O (0.15-0.20 M KCI) and p30 (0.3-0.4 M KCI) were determined by radioimmunoassays designed to detect interspecies antigenic determinants of each protein (25, 26) . Viral proteins were radiolabeled with 125I by the method of Greenwood et al. (27) .
FOCMA Antibody Detection. The procedure for titration of FOCMA antibody by indirect membrane immunofluorescence has been described in detail (6, 8 
RESULTS
Quantitation of FeLV gp7O and p30 in sera of FeLVexposed cats Radioiodinated FeLV viral proteins gp70 and p30 possessed molecular weights of around 75,000 to 80,000 and 30,000, respectively, by sodium dodecyl sulfate/polyacrylamide gel electrophoresis and exhibited over 95% radiochemical purity (Fig. 1 ). These were shown to be the major glycoprotein and structural proteins of FeLV by several criteria. Their molecular weights were analogous to those of glycoproteins and structural components of other mammalian type C viruses. Furthermore, antisera prepared against gp7O and p30 of Rauscher murine leukemia virus (R-MuLV) specifically precipitated the corresponding FeLV proteins, indicating that these proteins shared antigenic determinants with known type C viral gp7O and p30. In initial studies, sera from cats exposed to FeLV were tested for FeLV proteins by competition radioimmunoassay. As shown in Fig. 2 , several of the sera tested lacked any detectable FeLV gp7O or p30 as determined by radioimmunoassay. In other sera, both viral proteins were present at readily detectable, and in general coordinate, levels. These data correlate very well with previous studies by Hardy et (0) Table 1 . Titers of antibody to FOCMA, FeLV gp7O, and p30 in a previously uninfected cat that was contact-exposed to FeLV-infected cats Weeks after exposure   Test antigen  0  8  13  19  27  34  43  52   FeLV gp7O*  <40  <40  <40  <40  <40  1280  640  1280  FeLV p3O*  <40  <40  <40  <40  <40  640  320  640   FOCMAt   0  0  0  4  32  64  128  64 Data are given as the reciprocal of the highest 2-fold serum dilution yielding a positive result. * As determined by radioimmunoprecipitation. t As determined by indirect membrane immunofluorescence. gp70 on FOCMA-positive feline tumor cells that produce FeLV, several lines of evidence indicate a clear separation of these antigenic reactivities. Firstly, antibody to gp7O and p30 was never found in serum samples from viremic cats, even though such cats frequently exhibited high FOCMA antibody titers. Second, studies with sequential serum samples from an FeLV-exposed cat illustrate that FOCMA antibody can arise independently from antibodies to gp7O and p30 in nonviremic animals. Third, viremic cats with high FOCMA antibody titers demonstrated levels of circulating viral antigens similar to those in viremic cats that lacked detectable FOCMA antibody. This lack of correlation between amounts of virus antigens and FOCMA antibody titer suggests that gp7O and p30 do not absorb FOCMA antibody in vivo. Finally, exhaustive absorption of antiserum that had antibody to FOCMA, gp7O, and p30 with purified gp7O or p30 markedly reduced antibody activity to these virion structural proteins without reduction in FOCMA antibody activity.
The present findings are consistent with previous studies in which FeLV-neutralizing antibody was shown to be distinct from FOCMA antibody (3, 4, 7, 10, 23, 28) . In those studies, healthy viremic cats, which lacked detectable virus neutralizing antibody, often exhibited high FOCMA antibody titers (3, 4, 10) . Available evidence indicates that virus neutralization can be elicited by antisera prepared against purified viral gp7O (29-31). However, this viral protein contains a broad range of antigenic determinants detectable by immunoprecipitation, only some of which are involved in neutralization (26, 32) . Thus, unlike the present studies that involved precipitation of 125I-labeled gp7O, the previous studies could not exclude the possibility that FOCMA consisted of antigenic determinants of gp70 distinct from those involved in neutralization.
Recently, Ruscetti et al. reported that FOCMA antibody is indistinguishable from antibody directed against FeLV gp7O (19) . These studies utilized an 125I-antiglobulin-cell binding assay for titration of FOCMA rather than the standard mem- (35, 36) . In another study it was found that the Moloney oncornavirus cell surface antigen (MCSA) was distinct from antigens that could be detected using goat or rabbit antisera to Friend virus p15 or gp7O or Rauscher virus gp7O, p30, or p12 (37) . The possibility that FOCMA is FeLV p15 is considered unlikely in view of the fact that only very minimal amounts of this protein are present on reference target cells that are strongly positive for FOCMA (16, 17 
